Candel Therapeutics (CADL) Revenue (2020 - 2022)

Candel Therapeutics has disclosed Revenue across 3 years of filings, most recently posting $31000.0 for Q4 2022.

• Revenue for Q4 2022 came in at $31000.0, up 416.67% year-over-year; the trailing twelve-month figure through Dec 2022 was $124000.0 (up 25.25% YoY), and the FY2022 annual result was $125000.0, up 25.0% from the prior year.
• Revenue came in at $31000.0 for Q4 2022 at Candel Therapeutics, roughly flat from $31000.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $31000.0 in Q2 2020 to a low of $6000.0 in Q4 2021.
• The 3-year median for Revenue is $31000.0 (2020), against an average of $28727.3.
• Across the five-year window, Revenue plunged 80.65% in 2021 and surged 416.67% in 2022, its largest moves.
• Candel Therapeutics' Revenue stood at $31000.0 in 2020, then slumped by 80.65% to $6000.0 in 2021, then soared by 416.67% to $31000.0 in 2022.
• The last three Revenue figures came in at $31000.0 (Q4 2022), $31000.0 (Q3 2022), and $31000.0 (Q2 2022), per Business Quant data.